Takara Bio Inc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Takara Bio Inc with three other
companies in this sector in Japan:
Linical Company Limited
sales of 9.11 billion Japanese Yen [US$82.38 million]
of which 90%
was Cro Business),
Shin Nippon Biomedical Laboratories Ltd
(16.60 billion Japanese Yen [US$150.07 million]
of which 84%
was Pre-Clinical Business), and
Morishita Jintan Co., Ltd.
(10.80 billion Japanese Yen [US$97.63 million]
of which 75%
was Health Care Business).
Takara Bio Inc reported sales of ¥32.31 billion (US$292.10 million)
March of 2018.
increase of 10.0%
versus 2017, when the company's sales were ¥29.38 billion.
Sales of Bio Support saw an increase
11.3% in 2018, from
¥26.57 billion to ¥29.57 billion.
Not all segments of Takara Bio Inc experienced an increase in sales in 2018:
sales of Food and Bio Medical fell 2.5% to ¥2.24 billion.